Molecular Partners Forms Scientific Advisory Board for Radiopharmaceuticals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Molecular Partners announced the formation of a Scientific Advisory Board for its radiopharmaceuticals, chaired by Prof. Ken Herrmann, Chair of the Department of Nuclear Medicine at University Hospital Essen, Germany. The SAB also includes: radiopharmaceutical industry executive James Cook, previously founder and CEO of Evergreen Theragnostics and U.S. Chief Operating Officer at Advanced Accelerator Applications, where his team commercially launched Lutathera and Netspot; radiochemist Prof. Jason Lewis, Ph.D., the Emily Tow Chair in Oncology at Memorial Sloan Kettering Cancer Center and a Deputy Director of the Sloan Kettering Institute; and medical oncologist and nuclear medicine specialist Prof. Michael Morris, M.D., Steven A. Greenberg Chair in Prostate Cancer Research and Prostate Cancer Section Head at the Memorial Sloan Kettering Cancer Center.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MOLN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MOLN
Wall Street analysts forecast MOLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MOLN is 10.00 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.150
Low
8.00
Averages
10.00
High
12.00
Current: 4.150
Low
8.00
Averages
10.00
High
12.00
About MOLN
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wall Street Analysts Adjust Ratings on Key Stocks
- Visa Rating Upgrade: Cantor Fitzgerald analyst Ramsey El-Assal initiated coverage on Visa Inc (NYSE:V) with an Overweight rating and a price target of $400, indicating significant upside from Monday's closing price of $328.49, reflecting confidence in its future growth.
- Intuitive Surgical New Rating: TD Cowen analyst Mathew Blackman initiated coverage on Intuitive Surgical Inc (NASDAQ:ISRG) with a Buy rating and a price target of $660, which, compared to its Monday closing price of $528.81, highlights market recognition of its innovative technologies.
- Molecular Partners Buy Rating: HC Wainwright & Co. analyst Robert Burns initiated coverage on Molecular Partners AG (NASDAQ:MOLN) with a Buy rating and a price target of $13, representing significant upside from its Monday closing price of $4.00, indicating optimistic market expectations regarding its R&D progress.
- Mastercard Rating Upgrade: Cantor Fitzgerald analyst Ramsey El-Assal initiated coverage on Mastercard Inc (NYSE:MA) with an Overweight rating and a price target of $650, showing a positive outlook based on its Monday closing price of $527.36, reflecting confidence in its market performance.
Continue Reading
Molecular Partners Initiates MP0712 Clinical Trial, First Patient Dosing Expected Q1 2026
- Clinical Trial Launch: Molecular Partners has initiated a Phase 1/2a clinical trial for MP0712 in the US, with first patient dosing expected in Q1 2026, aiming to assess safety and determine the recommended dose, thereby enhancing the company's leadership in targeted radiotherapy.
- Strong Cash Position: As of December 31, 2025, the company reported cash and cash equivalents of CHF 93.1 million, which is projected to fund operating expenses and capital expenditures until 2028, ensuring the company's capacity for R&D and market expansion in the coming years.
- New Drug Development Progress: The Phase 2 trial for MP0317 is now open, targeting 75 patients to evaluate the clinical benefits of its combination with standard care, thereby strengthening the company's competitive position in cholangiocarcinoma treatment.
- Multi-Target Therapy: The Phase 1/2a trial for MP0533 is ongoing, with preliminary data indicating good tolerability and antitumor activity in acute myeloid leukemia patients, with an update on the clinical development path expected in H1 2026, further solidifying the company's product pipeline.
Continue Reading